A Phase 1 interventional study of Telotristat etiprate in Renal Impairment, sponsored by Ipsen. Completed at 4 sites in 4 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-08.
Sponsored by Ipsen · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Renal Insufficiency with a site in Belgium — 4 open to participants now, 6 under way, 1 of them phase 3. Renal Insufficiency · Belgium.
Among the 33 studies in Renal Insufficiency with a site in Belgium, this one is the 20th largest by enrollment of the 23 interventional ones that give a count, is one of 4 that started in 2018, is one of 3 in phase 1, and was the 26th registered.
1,414 studies on the registry are indexed under Renal Insufficiency; 147 are open to participants now.
Browse Renal Insufficiency studies →4 of the 33 studies in Renal Insufficiency with a site in Belgium are open now. Recruiting first, the newest first:
Takeda · Sites in Belgium, Estonia, France and 4 more countries
Ages 18+
Medtronic · Sites in Belgium, United States, Argentina and 38 more countries
Universitaire Ziekenhuizen KU Leuven · Sites in Belgium
Rigshospitalet, Denmark · Sites in Belgium, Argentina, Austria and 33 more countries
Ages 16+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 93 Renal Insufficiency studies recruiting now, 49 (53%) set no upper age limit and 19 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 5 · Phase 4 4
First in 1994; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 16 is below the median of 40 across 1,062 interventional studies indexed under Renal Insufficiency.
Median enrollment 117 across the 23 interventional studies, 323 across the 10 observational. Of the 25 that completed or were terminated, 15 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 33 have an industry lead sponsor. The 10 most frequent:
Ipsen is the lead sponsor of 290 studies on the registry; 18 are open to participants now.
Of its 26 completed or terminated interventional studies of FDA-regulated products, 22 (85%) have results posted.
Ipsen has 1 study filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
2 of the studies in Renal Insufficiency with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT06243731TakedaA Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation | 2027-01-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 33 studies in Renal Insufficiency with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Renal excretion is a minor elimination route of telotristat etiprate. So this trial is intended to assess the drug behaviour in subjects with decreased renal function.
This is a staged study with Part B contingent upon the results of Part A. Part A will enrol a total of 16 subjects, eight with severely impaired renal function and eight healthy subjects. Part B with enrol a total of 16 subjects, eight subjects in each additional renal function group, i.e. mildly impaired renal function group and moderately impaired group.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
All subjects:
Additionally, for subjects with renal impaired function:
Additionally, for healthy subjects with normal renal function:
Exclusion Criteria:
All subjects:
Additionally, for renal impaired subjects:
Additionally, for healthy subjects with normal renal function:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
Drug: Telotristat etiprate
Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
Drug: Telotristat etiprate
Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
Drug: Telotristat etiprate
Subjects will receive a single oral 250-mg tablet dose of Telotristat etiprate (Xermelo® 250 mg) on day 1 under fed conditions (i.e. between 15 minutes before and 1 hour after the meal or snack).
Drug: Telotristat etiprate
Oral administration of 1 tablet of Xermelo® containing telotristat etiprate equivalent to 250 mg telotristat ethyl.
Also known as: Xermelo®
Maximum Plasma Concentration (Cmax) of Total Telotristat Ethyl, LP-778902 and LP-951757
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) bioanalytical method with a lower limit of quantitation (LOQ) of 0.5 nanograms (ng)/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. Cmax was determined using non-compartmental analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Time to Maximum Observed Plasma Concentration (Tmax) of Total Telotristat Ethyl, LP-778902 and LP-951757
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. Tmax was determined using non-compartmental analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Apparent Terminal Elimination Half-Life (t1/2) of Total Telotristat Ethyl, LP-778902 and LP-951757
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. T1/2 was determined using non-compartmental analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Area Under the Plasma Concentration-Time Curve From Time 0 to Infinity (AUC0-inf) of Total Telotristat Ethyl, LP-778902 and LP-951757
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. AUC0-inf was determined using non-compartmental analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Area Under the Plasma Concentration-Time Curve From Time 0 to Time Corresponding to the Last Quantifiable Concentration (AUC0-tlast) of Total Telotristat Ethyl, LP-778902 and LP-951757
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. AUC0-tlast was determined using non-compartmental analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Apparent First Order Terminal Elimination Rate Constant (λz) of Total Telotristat Ethyl, LP-778902 and LP-951757
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. λz was determined using non-compartmental analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Apparent Total Clearance From Plasma (CL/F) of Total Telotristat Ethyl
Blood samples were collected to determine plasma levels of telotristat ethyl using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL. CL/F was determined using non-compartmental analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Apparent Volume of Distribution (Vd/F) of Total Telotristat Ethyl
Blood samples were collected to determine plasma levels of telotristat ethyl using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL. Vd/F was determined using non-compartmental analysis.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Percentage of Unbound Plasma Fraction (fu) of Total Telotristat Ethyl, LP-778902 and LP-951757
Plasma protein binding was assessed using equilibrium dialysis followed by LC-MS/MS for determination of unbound drug concentrations. The plasma protein binding of telotristat ethyl, LP-778902 and LP-951757 was assessed and the percentage of fu was calculated as the mean over time of the mean of the available replicates.
Time frame: Day 1 (0.5, 1, 2 and 3 hours post-dose)
Cmax for the Unbound Fraction (Cmaxu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757
Cmaxu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.
Time frame: Day 1 (0.5, 1, 2 and 3 hours post-dose)
AUC0-inf for the Unbound Fraction (AUC0-infu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757
AUC0-infu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.
Time frame: Day 1 (0.5, 1, 2 and 3 hours post-dose)
AUC0-tlast for the Unbound Fraction (AUC0-tlastu) of Unbound Telotristat Ethyl, LP-778902 and LP-951757
AUC0-tlastu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.
Time frame: Day 1 (0.5, 1, 2 and 3 hours post-dose)
Metabolic Ratios (MR) of Cmax (LP-778902/Telotristat Ethyl)
The following MRs of Cmax were calculated: MRCmax = (Cmax LP-778902)/(Cmax telotristat ethyl) MRCmaxTotal = (Cmax LP-778902)/(Cmax LP-778902+Cmax telotristat ethyl) The ratios were also normalised by molecular weight (MW) of the metabolites (telotristat ethyl: MW=575 grams/mole (g/mol) and LP-778902: MW=547 g/mol). Both the normalised and not normalised ratios are presented.
Time frame: Day 1 (pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 12 hours), Day 2 (24 hours), Day 3 (48 hours) and Day 4 (72 hours)
Amount of Unchanged Telotristat Ethyl and LP-778902 Excreted in Urine.
For assessment of urine PK parameters, the amount of unchanged telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) excreted in urine was determined.
Time frame: Day 1 (predose and 0 to 4 hours, 4 to 8 hours, 8 to 12 hours, 12 to 24 hours post-dose), Day 2 (24 to 48 hours post-dose), Day 3 (48 to 72 hours post-dose)
A total of 16 subjects were recruited in this open label, single dose study between February and May 2018. Recruited subjects were split evenly between 2 groups (control group and test group).
| Milestone | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) bioanalytical method with a lower limit of quantitation (LOQ) of 0.5 nanograms (ng)/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. Cmax was determined using non-compartmental analysis.
| ng/mL | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | 3.81 ± 98.9 | 4.94 ± 116 |
| LP-778902 | 533 ± 58.1 | 759 ± 52.9 |
| LP-951757 | 65.2 ± 46.0 | 45.6 ± 80.2 |
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. Tmax was determined using non-compartmental analysis.
| hours | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | 1.03 (0.500 to 3.00) | 1.00 (0.500 to 3.00) |
| LP-778902 | 2.00 (1.00 to 4.00) | 2.50 (1.00 to 3.00) |
| LP-951757 | 4.00 (3.00 to 8.00) | 4.00 (2.02 to 6.00) |
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. T1/2 was determined using non-compartmental analysis.
| hours | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | NA ± NA | NA ± NA |
| LP-778902 | 9.05 ± 3.02 | 8.31 ± 1.51 |
| LP-951757 | 11.5 ± 4.65 | 9.93 ± 4.45 |
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. AUC0-inf was determined using non-compartmental analysis.
| ng*hour/mL | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | NA ± NA | NA ± NA |
| LP-778902 | 1652 ± 42.7 | 2488 ± 77.9 |
| LP-951757 | 876 ± 66.0 | 511 ± 115 |
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. AUC0-tlast was determined using non-compartmental analysis.
| ng*hour/mL | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | NA ± NA | NA ± NA |
| LP-778902 | 1637 ± 43.3 | 2475 ± 78.3 |
| LP-951757 | 845 ± 64.4 | 494 ± 118 |
Blood samples were collected to determine plasma levels of telotristat ethyl, its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL for telotristat ethyl and 2 ng/mL for LP-778902 and LP-951757. λz was determined using non-compartmental analysis.
| hour^-1 | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | NA ± NA | NA ± NA |
| LP-778902 | 0.0890 ± 0.0469 | 0.0871 ± 0.0236 |
| LP-951757 | 0.0686 ± 0.0238 | 0.0821 ± 0.0381 |
Blood samples were collected to determine plasma levels of telotristat ethyl using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL. CL/F was determined using non-compartmental analysis.
| Litres/hour | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Apparent Total Clearance From Plasma (CL/F) of Total Telotristat Ethyl | NA ± NA | NA ± NA |
Blood samples were collected to determine plasma levels of telotristat ethyl using a validated, specific and sensitive LC-MS/MS bioanalytical method with a LOQ of 0.5 ng/mL. Vd/F was determined using non-compartmental analysis.
| Litres | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Apparent Volume of Distribution (Vd/F) of Total Telotristat Ethyl | NA ± NA | NA ± NA |
Plasma protein binding was assessed using equilibrium dialysis followed by LC-MS/MS for determination of unbound drug concentrations. The plasma protein binding of telotristat ethyl, LP-778902 and LP-951757 was assessed and the percentage of fu was calculated as the mean over time of the mean of the available replicates.
| Percentage of fu | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | NA ± NA | NA ± NA |
| LP-778902 | 0.115 ± 0.0589 | 0.134 ± 0.0524 |
| LP-951757 | 0.135 ± 0.295 | 0.0608 ± 0.0923 |
Cmaxu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.
| ng/mL | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | NA ± NA | NA ± NA |
| LP-778902 | 0.554 ± 113 | 0.957 ± 70.7 |
| LP-951757 | 0.0528 ± 215 | 0.0779 ± 84.0 |
AUC0-infu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.
| ng*hour/mL | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | NA ± NA | NA ± NA |
| LP-778902 | 1.72 ± 90.3 | 3.14 ± 99.2 |
| LP-951757 | 0.955 ± 237 | 1.06 ± NA |
AUC0-tlastu of unbound telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) and the inactive metabolite LP-951757 was calculated using the unbound fraction fu (defined for each subject as the mean over all time points of the mean of fu) and determined using non-compartmental analysis.
| ng*hour/mL | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| Telotristat Ethyl | NA ± NA | NA ± NA |
| LP-778902 | 1.70 ± 91.2 | 3.12 ± 99.6 |
| LP-951757 | 0.928 ± 234 | 1.05 ± NA |
The following MRs of Cmax were calculated: MRCmax = (Cmax LP-778902)/(Cmax telotristat ethyl) MRCmaxTotal = (Cmax LP-778902)/(Cmax LP-778902+Cmax telotristat ethyl) The ratios were also normalised by molecular weight (MW) of the metabolites (telotristat ethyl: MW=575 grams/mole (g/mol) and LP-778902: MW=547 g/mol). Both the normalised and not normalised ratios are presented.
| Ratio | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| MRCmax - not normalised | 154 ± 68.9 | 204 ± 143 |
| MRCmax - normalised | 162 ± 72.4 | 215 ± 151 |
| MRCmaxTotal - not normalised | 0.992 ± 0.00410 | 0.991 ± 0.00996 |
| MRCmaxTotal - normalised | 0.993 ± 0.00391 | 0.991 ± 0.00949 |
For assessment of urine PK parameters, the amount of unchanged telotristat ethyl and its active metabolite LP-778902 (also known as telotristat) excreted in urine was determined.
| ng | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| LP-778902: Pre-dose | 0 ± 0 | 0 ± 0 |
| LP-778902: 0-4 hours post-dose | 88966 ± 50003 | 19293 ± 9447 |
| LP-778902: 4-8 hours post-dose | 152419 ± 48649 | 42976 ± 22836 |
| LP-778902: 8-12 hours post-dose | 173416 ± 49499 | 47955 ± 25522 |
| LP-778902: 12-24 hours post-dose | 185970 ± 47726 | 51970 ± 27925 |
| LP-778902: 24-48 hours post-dose | 191999 ± 48110 | 53997 ± 29262 |
| LP-778902: 48-72 hours post-dose | 193880 ± 48123 | 54397 ± 29546 |
Collected over Treatment emergent adverse events were recorded from Day 1 to the end of study visit between Day 8 and Day 15 (overall timeframe: up to 15 days).. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Healthy Subjects (Control Group) | 0/8 (0%) | 0/8 (0%) | 1/8 (12.5%) |
| Severe Renal Impairment (Test Group) | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| Event | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) |
|---|---|---|
| C-reactive protein increasedInvestigations | 0/8 | 1/8 |
| Heart rate increasedInvestigations | 0/8 | 1/8 |
| Lymphocyte count decreasedInvestigations | 0/8 | 1/8 |
| Monocyte count increasedInvestigations | 0/8 | 1/8 |
| Back painMusculoskeletal and connective tissue disorders | 0/8 | 1/8 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 0/8 | 1/8 |
| LeukocytosisBlood and lymphatic system disorders | 1/8 | 0/8 |
| NauseaGastrointestinal disorders | 0/8 | 1/8 |
| ChillsGeneral disorders | 0/8 | 1/8 |
| BronchitisInfections and infestations | 0/8 | 1/8 |
| Age, Categorical(Participants) | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 6 | 13 |
| >=65 years | 1 | 2 | 3 |
| Sex: Female, Male(Participants) | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) | Total |
|---|---|---|---|
| Female | 3 | 3 | 6 |
| Male | 5 | 5 | 10 |
| Race (NIH/OMB)(Participants) | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 8 | 8 | 16 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Healthy Subjects (Control Group) | Severe Renal Impairment (Test Group) | Total |
|---|---|---|---|
| Romania | 3 | 3 | 6 |
| Belgium | 1 | 3 | 4 |
| Moldova | 2 | 0 | 2 |
| Germany | 2 | 2 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Feb 2018 to primary completion in Apr 2018, 2 months.
Results were first posted in Sep 2019, 1 year 4 months after primary completion.
Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 2 months is below that.
Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Telotristat ethyl